Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Cancer Journal

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 11038138
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models

  2009cited by this paper
• Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C

  2004cited by this paper
• Protein Kinase C Targeting in Antineoplastic Treatment Strategies

  2004cited by this paper
• Flavopiridol: the First Cyclin-Dependent Kinase Inhibitor in Human Clinical Trials

  2004cited by this paper
• Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells

  2004cited by this paper
• The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.

  2000cited by this paper
• Preclinical and clinical development of cyclin-dependent kinase modulators.

  2000cited by this paper
• The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1.

  2000cited by this paper
• Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells.

  2000cited by this paper
• The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01*

  2000cited by this paper
• Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study.

  2000cited by this paper
• UCN‐01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G2 checkpoint abrogation

  2000cited by this paper
• Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors, and agents in development.

  1999cited by this paper
• Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor.

  1999cited by this paper
• Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell line.

  1999cited by this paper
• A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats.

  1999cited by this paper
• Novel small molecule alpha v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors.

  1999cited by this paper
• Enzymatic rationale and preclinical support for a potent protein kinase C beta inhibitor in cancer therapy.

  1999cited by this paper
• Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells.

  1999cited by this paper
• The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients.

  1999cited by this paper
• Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer.

  1999cited by this paper
• Disruption of p53 in human cancer cells alters the responses to therapeutic agents.

  1999cited by this paper
• Cyclins and cell cycle checkpoints.

  1999cited by this paper
• Apoptosis and carcinogenesis.

  1999cited by this paper
• Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists.

  1999cited by this paper
• Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer.

  1999cited by this paper
• Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis.

  1999cited by this paper
• In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer

  1999cited by this paper
• Mechanism of inhibition of P-glycoprotein-mediated drug transport by protein kinase C blockers.

  1999cited by this paper
• Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases.

  1999cited by this paper
• Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation In vivo after carotid injury in the rat.

  1999cited by this paper
• Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent.

  1999cited by this paper
• Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole.

  1999cited by this paper
• Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity.

  1999cited by this paper
• Apoptosis and cancer drug targeting.

  1999cited by this paper
• Characterization of a Potent and Specific Class of Antisense Oligonucleotide Inhibitor of Human Protein Kinase C-α Expression*

  1999cited by this paper
• CDK inhibitors: positive and negative regulators of G1-phase progression.

  1999cited by this paper
• Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target.

  1999cited by this paper
• Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes.

  1999cited by this paper
• Treatment of patients with metastatic melanoma with bryostatin-1--a phase II study.

  1999cited by this paper
• Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol.

  1999cited by this paper
• Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice.

  1998cited by this paper
• Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells.

  1998cited by this paper
• Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol.

  1998cited by this paper
• Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-alpha.

  1998cited by this paper
• Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.

  1998cited by this paper
• Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

  1998cited by this paper
• Phase Ib trial of bryostatin 1 in patients with refractory malignancies.

  1998cited by this paper
• Multimodality therapy: radiation and continuous concomitant cis-platinum and PKC inhibition in a cervical carcinoma model.

  1998cited by this paper
• Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531.

  1998cited by this paper
• Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

  1998cited by this paper
• Dysregulation of apoptosis in cancer.

  1998cited by this paper
• Caffeine and staurosporine enhance the cytotoxicity of cisplatin and camptothecin in human brain tumor cell lines.

  1998cited by this paper
• Human and yeast cdk-activating kinases (CAKs) display distinct substrate specificities.

  1998cited by this paper
• Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.

  1998cited by this paper
• Calphostin C triggers calcium-dependent apoptosis in human acute lymphoblastic leukemia cells.

  1998cited by this paper
• Growth inhibition induced by Ro 31-8220 and calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase.

  1998cited by this paper
• Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937).

  1998cited by this paper
• UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner.

  1998cited by this paper
• Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts.

  1998cited by this paper
• Treatment of human glioblastoma cells with the staurosporine derivative CGP 41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivity.

  1998cited by this paper
• A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin.

  1997cited by this paper
• G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells.

  1997cited by this paper
• High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers.

  1997cited by this paper
• 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells.

  1997cited by this paper
• Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.

  1997cited by this paper
• Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation.

  1997cited by this paper
• 7-Hydroxystaurosporine (UCN-01) induces apoptosis in human colon carcinoma and leukemia cells independently of p53.

  1997cited by this paper
• The effect of UCN-01 (7-hydroxystaurosporine), a potent inhibitor of protein kinase C, on fractionated radiotherapy or daily chemotherapy of a murine fibrosarcoma.

  1997cited by this paper
• Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis.

  1997cited by this paper
• Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.

  1997cited by this paper
• Different sensitivities of neutrophil responses to a selective protein kinase C inhibitor Ro 31-8425; redundancy in signal transduction.

  1997cited by this paper
• Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function.

  1997cited by this paper
• Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy.

  1997cited by this paper
• The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines.

  1997cited by this paper
• Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism.

  1997cited by this paper
• Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard

  1997cited by this paper
• Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells.

  1996cited by this paper
• Ubiquitination of protein kinase C-alpha and degradation by the proteasome.

  1996cited by this paper
• UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line.

  1996cited by this paper
• Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.

  1996cited by this paper
• UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.

  1996cited by this paper
• (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.

  1996cited by this paper
• Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor.

  1996cited by this paper
• Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter.

  1996cited by this paper
• Bcl-xL overexpression inhibits taxol-induced Yama protease activity and apoptosis.

  1996cited by this paper
• The Selective Protein Kinase C Inhibitor, Ro-31-8220, Inhibits Mitogen-activated Protein Kinase Phosphatase-1 (MKP-1) Expression, Induces c-Jun Expression, and Activates Jun N-terminal Kinase*

  1996cited by this paper
• Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

  1996cited by this paper
• Spectroscopic imaging of human brain glutamate by water‐suppressed J‐refocused coherence transfer at 4.1 T

  1996cited by this paper
• A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.

  1996cited by this paper
• Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor.

  1996cited by this paper
• Radiosensitization of HL-60 human leukaemia cells by bryostatin-1 in the absence of increased DNA fragmentation or apoptotic cell death.

  1996cited by this paper
• Differential effects of staurosporine analogues on cell cycle, growth and viability in A549 cells.

  1996cited by this paper
• Protease activation during apoptosis: death by a thousand cuts?

  1995cited by this paper
• Analyses of protein kinase C isoform expression in a colorectal cancer liver metastasis model.

  1995cited by this paper
• Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck.

  1995cited by this paper
• Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes

  1995cited by this paper
• A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.

  1995cited by this paper
• Apoptosis of human glioma cells in response to calphostin C, a specific protein kinase C inhibitor.

  1995cited by this paper
• Antitumoral activity of flavone L-86-8275.

  1995cited by this paper

• intracellulaires par chromatographie d'anit e

  2015cites this paper
• A single‐molecule force spectroscopy nanosensor for the identification of new antibiotics and antimalarials

  2010cites this paper
• Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machines.

  2010cites this paper
• Evaluation of natural products in apoptosis, protein kinase C activation and Caco-2 Cell permeability

  2008cites this paper
• The Discovery of Anticancer Drugs From Natural Sources

  2005cites this paper
• Therapeutic potential of natural compounds that regulate the activity of protein kinase C.

  2004cites this paper
• Novel therapeutic targets in squamous cell carcinoma of the head and neck.

  2004cites this paper
• Bryostatin Induces Protein Kinase C Modulation, Mcl-1 Up-Regulation and Phosphorylation of Bcl-2 Resulting in Cellular Differentiation and Resistance to Drug-induced Apoptosis in B-cell Chronic Lymphocytic Leukemia Cells

  2004cites this paper
• Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo.

  2003cites this paper
• Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.

  2003cites this paper
• Protein kinase inhibitors as a therapeutic modality.

  2003cites this paper
• Efficient synthesis of enantiomerically pure 2-acylaziridines: Facile syntheses of N-Boc-safingol, N-Boc-D-erythro-sphinganine, and N-Boc-spisulosine from a common intermediate.

  2003cites this paper
• Protein kinase C‐delta is commonly expressed in multiple myeloma cells and its downregulation by rottlerin causes apoptosis

  2003cites this paper
• Novel Anticancer Agents in Clinical Development

  2003cites this paper
• Plants as a source of anti-cancer and anti-HIV agents

  2003cites this paper
• CHAPTER 77 – Protein Kinase Inhibitors

  2003cites this paper
• p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol

  2002cites this paper
• Apoptosis: target of cancer therapy.

  2002cites this paper
• Mécanismes d'action des inhibiteurs de kinases cyclines-dépendantes : identification de leurs cibles intracellulaires par chromatographie d'affinité

  2002cites this paper
• Higher levels of melanin and inhibition of cdk2 activity in primary human melanoma cells WM115 overexpressing nPKC

  2002cites this paper
• Molecular Mechanisms of the Cross-Impact of Pathological Processes in Combined Diabetes and Cancer. Research and Clinical Aspects

  2002cites this paper
• LY900003 (Affinitac), an antisense inhibitor of protein kinase C-alpha, in non-small-cell lung cancer.

  2002cites this paper
• Natural products and derivatives as leads to cell cycle pathway targets in cancer chemotherapy.

  2002cites this paper
• Control of proliferation in the normal and neoplastic breast

  2002cites this paper
• Critical appraisals of approaches for predictive designs in anticancer drugs

  2002cites this paper
• Mother nature's combinatorial libraries; their influence on the synthesis of drugs.

  2002cites this paper
• Higher levels of melanin and inhibition of cdk2 activity in primary human melanoma cells WM115 overexpressing nPKCδ

  2002cites this paper
• Identifying in vivo targets of cyclin-dependent kinase inhibitors by affinity chromatography.

  2002cites this paper
• LY900003 (Affinitac™), an Antisense Inhibitor of Protein Kinase C—α, in Non—Small-Cell Lung Cancer

  2002cites this paper
• Selected Targets and Rationally Designed Therapeutics for Patients with Colorectal Cancer

  2002cites this paper
• Protein kinase C inhibitors as novel anticancer drugs

  2001cites this paper
• The Cyclin-dependent Kinases cdk2 and cdk5 Act by a Random, Anticooperative Kinetic Mechanism*

  2001cites this paper
• 2001 Highlights From: 37th Annual American Society of Clinical Oncology Meeting San Francisco, CA May 12–15, 2001

  2001cites this paper
• Highlights from: 37th Annual American Society of Clinical Oncology Meeting San Francisco, CA, May 12-15, 2001.

  2001cites this paper
• Novel pharmacological agents in clinical development for solid tumours

  2001cites this paper
• 37th Annual American Society of Clinical Oncology Meeting. San Francisco, CA. May 12-15, 2000.

  2001cites this paper